Adult T cell leukaemia: A review of established and new treatments

BioDrugs

Volumn 10, Issue 6, 1998, Pages 447-462

  Hermine, Olivier ^a   Wattel, Eric ^b   Gessain, Antoine ^c   Bazarbachi, Ali ^d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Institut Pasteur   (France)

^d AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BESTRABUCIL; BETA INTERFERON; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISOLONE; PROCARBAZINE; RANIMUSTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LEUKEMIA; VIRUS CARCINOGENESIS;

EID: 0032425056     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810060-00003     Document Type: Review

References (118)

1. Hinuma Y, Komoda H, Chosa T, et al. Antibodies to adult T-cell leukemia-virus associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation wide seroepidemiologic study. Int J Cancer 1982; 29: 631-5
2. Kaplan J, Khahhaz R. The epidemiology of human T-lymphotropic virus type I and II. Med Virol 1993; 3: 137-48
3. Gessain A. Epidemiology of HTLV-1 and associated diseases. In: Höllsberg P, Hafler DA. Human T-cell lymphotropic virus type 1 .New York: John Willey & Sons Ltd 1996: 33-64
4. Murphy E, Hanchard B, Figueroa J, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43: 250-3
5. Hino S. Maternal-infant transmission of HTLV-1: implication for disease. In: Blattner WA, editor. Human retrovirology: HTLV. New York: Raven Press, 1990: 363-8
6. Gessain A, Saal F, Gout O, et al. High human T-cell lymphotropic virus type 1 proviral DNA load w ith polyclonal integration in peripheral blood mononuclear cells of French West Indian. Guianese, and African patients with tropical spastic paraparesis. Blood 1990; 75 (2): 428-33
7. Wattel E, Mariotti M, Agis F, et al. Quantification of HTLV-1 proviral copy numher in peripheral blood of symptomless carriers from the French West Indies. J Acquir Immune Defic Syndr 1992; 5 (9): 943-6
8. Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type 1 genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66 (4): 2288-95
9. Holland J, Spindler K, Horodyski F, et al. Rapid evolution of RNA genomes. Science 1982; 215: 1577-85
10. Wattel E, Vartanian JP, Pannetier C, et al. Clonal expansion of human T-cell leukemia virus type 1-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69 (5): 2863-8
11. Cavrois M, Gessain A, Wain-Hobson S, et al. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM. Oncogene 1996; 12 (11): 2419-3
12. Cavrois M, Wain-Hobson S, Gessain A, et al. Adult T-cell leukemia/lymphoma on a background of clonally expanding human T-cell leukemia virus type-1-positive cells. Blood 1996; 88: 4646-50
13. Furukawa Y, Fujisawa J, Osame M, et al. Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP). Blood 1992; 80 (4): 1012-6
14. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type 1 infection. Blood 1995; 86 (10): 3619-9
15. Yoshida M, Seiki M. Molecular biology of HTLV-1. Biological significance of viral genes in ils replication and leukemogenesis. In: Gallo R, Wong-Staal F, editors. Retrorus biology and human disease. New York: Marcel Decker, 1990: 161-86
16. Yoshida M: Tenth anniversary perspectives on AIDS. Host-HTLV type 1 infraction at the molecular level. AIDS Res Hum Retroviruses 1994; 10 (10): 1193-7
17. Smith M, Greene C. Molecular biology of the type 1 human T-cell leukemia virus (HTLV-1) and adult T-cell leukemia. J Clin Invest 1991: 87: 761-6
18. Yoshida M. Howard Temin memorial lectureship: molecular biology of HTLV-1 deregulation of hosl cell gene expression and cell cycle. Leukemia 1997: 11 (1) 14-5
19. Yoshida M. Multiple targets of HTLV-1 for dysregulation of host cells. Semin Virol 1996; 7: 349-60
20. Konichi H, Kobayashi N, Hatanaka M. Detective human T-cell leukemia virus in adult T-cell leukemia patients. Mol Biol Med 1984; 2: 273-9
21. Korber K, Okayama A, Donnelly R, et al. Polymerase chain reaction analysis of defective human T-cell leukemia virus type 1 proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol 1991; 65 (10): 5471-6
22. Ross T, Pettiford S, Green P. The Tax gene of human T-cell leukemia virus type 2 is essential for transformation of human T-lymphocytes. J Virol 1996; 70: 5194-202
23. Felber B, Paskalis H, Kleiman-Ewing E, et al. The pX protein of HTLV-1 is a transcriptional activator of its long terminal repeats. Science 1985: 229: 675-8
24. Greene W, Leonard W, Wano Y, et al. Transactivator gene of HTLV-1 induces IL-2 receptor and IL-2 cellular gene expression. Science 1986; 232: 877-80
25. Jeang K, Widen S, Semmes O, et al. HTLV-1 trans-activator protein Tax, is a trans repressor of the human β-polymerase gene. Science 1990; 247: 1082-4
26. Grossman R, Fleckenstein B, Desrosiers R. Viral transformation of human T lymphocytes. Adv Cancer Res 1994; 63: 211-43
27. Smith M, Greene W. Identification of HTLV-1 Tax transactivator mutants exhibiting novel transcriptional phenotypes. Genes Dev 1990; 4: 1875-83
28. Mulloy JC, Crownley RW, Fullen J, et al. The human T-cell leukemia/lymphotropic virus type 1 p121 proteins bind the interleukin-2 receptor beta and gamma chains and affects their expression on the cell surface. J Virol 1996; 70 (6): 3599-605
29. Migone T, Lin J, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T-cells transformed with HTLV-1. Science 1995; 269: 79-81
30. Maruyama K, Fukushima T, Kawamura K, et al. Chromosome and gene rearrangements in immortalized human lymphocytes infected with human T-lymphotropic virus type I. Cancer Res 1990; 50 (17 Suppl.): 5697S-702S
31. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79 (2): 477-80
32. Hatta Y, Hirama T, Miller CW, et al. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85 (10): 2699-704
33. Suzuki T, Kitao S, Matsushime H, et al. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p161NK4A and counteracts its inhibitory activity towards CDK4. Embo J 1996; 15 (7): 1607-4
34. Cereseto A, Diella F, Mulloy JC, et al. p53 functional impairment and high p21 waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type 1-transformed T cells. Blood 1996; 88 (5): 1551-60
35. Jin D, Spencer F, Jeang K, Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint MAD1. Cell 1998; 93: 81-91
36. Franchini G, Wong Staol F, Gasllo RC. Human T cell leukemia virus (HILV-1I) transcripts in fresh and cultured cells of patients with adult T cell leukemia. Proc Natl Acad Sci U S A 1984; 81: 6207-11
37. Yamaoka S, Tobe T, Hatanaka M. Tax protein of human T-cell leukemia virus type 1 is required for maintenance of the transformed phenotype. Oncogene 1992; 7 (3): 433-7
38. Tendler CL, Greenberg SJ, Blattner WA, et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type 1-associated myclopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci U S A 1990; 87 (13): 5218-22
39. Gessain A, Louie A, Gout O, et al. Human T-cell leukemia-lymphoma virus type 1 (HTLV-1) expression in fresh peripheral blood mononuclear cells from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy. J Virol 1991; 65 (3): 1628-33
40. Bazarbachi A, Saal F, Lasneret J, et al. Unintegrated HTLV-1 proviral DNA in cell lines and uncultured peripheral blood mononuclear cells from tropical spastic paraparesis (TSP/HAM) and adult T-cell leukemia (ATL) patients. C R Acad Sci III 1994; 317 (3): 264-9
41. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-1 provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 1997; 89: 948-56
42. Kannagi M, Sugamura K, Hirouuki S, et al. Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus bearing cells. J Immunol 1983; 130: 2942-8
43. Mitsuya H, Matis L, Megson M, et al. Generation of an HLA restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med 1983; 158: 994-1003
44. Zanke B, Rush D, Jeffery J, et al. HTLV-1 T cell lymphoma in a cyclosporine treated renal transplant patient. Transplantation 1989; 48: 695-7
45. Williams NP, Buchner LM, Shah DJ, et al. Adult T-cell leukemia/lymphoma in a renal transplant recipient: an opportunistic occurrence. Am J Nephrol 1994; 14(3): 226-9
46. Hanchard B. Adult T-cell leukemia/lymphoma in Jamaica: 1986-1995. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 13 Suppl. 1: S20-5
47. Bunn P, Schechter G, Jaffe E. Clinical course of retrovirus-associatecl adult T cell lymphoma in the United States. N Engl J Med 1983: 309: 257-64
48. Takatsuki F, Yamaguchi K, Hattori T. Adult T-cell leukemia/lymphoma. In: Gallo RC, Wong-Staal F. Retrovirus biology and human disease. 1990: 147-59
49. Takatsuki K, Matsuoka M, Yamaguchi K, Adult T-cell leukemia in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl. 1: S15-9
50. Pamdo-de-Oliveira MS, Matutes E, Schulz T, et al. T cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-1 positive and negative cases. Int J Cancer 1995; 16 (60): 823-7
51. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79 (3): 428-37
52. Shimoyama M, and members of the lymphoma study group. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia/lymphoma. Br J Haematol 1991; 79: 428-39
53. Wattel E, Cavrois M, Gessain A, et al. Clonal expansion of infected cells: A way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl. 1: S92-9
54. Wattel E, Vartanian JP, Pannetier C, et al. Clonal expansion of human T-cell leukemia virus type 1-intected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995; 69 (5): 2863-8
55. Takatsuki K: Adult T-cell leukemia. Intern Med 1995; 34 (10): 947-52
56. Lymphoma study group. Major prognostic factor of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res 1991; 15: 81-6
57. Shirono K, Hattori T, Takatsuki K. A new classification of clinical stages of adult T-cell leukemia based on prognosis of the disease. Leukemia 1994; 8: 1834-7
58. Kamihira S, Sohda H, Atogami S, et al. Phenotypic diversity and prognosis of adult T-cell leukemia. Leuk Res 1992; 16: 435-41
59. Sadamori N, Ikeda S, Yamaguchi K, et al. Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. Leuk Res 1991; 15: 99-103
60. Sadamori N, Mine M, Hakariya S, et al. Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia. Leukemia 1995; 9 (4): 594-7
61. Sadamori N, Mine M, Kasahara H. Clinical and biological significance of serum parathyroid hormone-related protein in adult T-cell leukemia [letter]. Leuk Res 1995; 19 (3): 229-30
62. Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin 2 receptors levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994; 73: 2753-8
63. Bunn Jr PA, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309 (5): 257-64
64. Amagasaki T, Tomonaga Y, Yamada Y, et al. Adult T-cell leukemia with an unusual phenotype, Leu 2a positive and Leu-3a negative. Blut 1985; 50: 209-11
65. Lorand-Metze I, Pambo-de-Oliveira NS. Adult T cell leukemia (ATL) with an unusual immunophenotype and a high cellular proliferation rate. Leuk Lymphoma 1996; 22: 523-6
66. Takemoto S, Matsuoka M, Yamaguchi K, et al. A novel diagnostic method of adult T-cell leukemia: monoclonal integration of human T-cell lymphotropic virus type 1 provirus DNA detected by inverse polymerase chain reaction. Blood 1994; 84 (9): 3080-5
67. Shimoyama M. Treatment of patients with adult T-celt leukemia-lymphoma: an overview. In: Takatsuki K, Hinuma Y, Yoshida M, editors. Advances in adult T-cell leukemia and HTLV-1 research: Japan scientific societies press. Gonn Monographs on Cancer Research 1992; 39: 43-56
68. Nakada K, Yamaguchi K, Furugen S, et al. Monoclonal integration of HTLV-I proviral DNA in patients with strongyloidiasis. Int J Cancer 1987; 40 (2): 145-8
69. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa [see comments]. N Engl J Med 1995; 332 (26): 1749-51
70. Uozumi K, Hanada S, Ohno N, et al. Combination chemotherapy (RCM protocol: response-oriented cyclic mutidrug protocol) for the acute or lymphoma type adult t-cell leukemia. Leuk Lymph 1995; 18:317-23
71. Taguchi H, Ken-Ichiro K, Takalsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12: 182-6
72. Sparano J, Wiernik P, Strack M, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type 1-related non hodgkin's lymphoma: a highly active regimen. Blood 1993; 81: 2810-5
73. Minato K, Araki K, Hanada S, et al. Lymphoma study group (LSG) an interim report of LGS4 treatment for advanced peripheral T-cell lymphoma. Int J Hematol 1991; 54 Suppl. 1: 179
74. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988; 6: 1088-97
75. Rio B, Louvet C, Gessain A, et al. Adult T-cell leukemia and non-malignant adenopathies associated with HTLV I virus. Apropos of 17 patients born in the Caribbean region and Africa. Presse Med 1990; 19 (16): 746-51
76. Taguchi H, Ken-Ichiro K, Takatsuki K, et al. Granulocyte-colony stimulating factor supported intensive chemotherapy of adult T cell leukemia/lymphoma. Blood 1994; 84 S1: 479a
77. Slevin M, Clark P, Joel S, et al. A randomized trial to evaluate effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-40
78. Matsushima Y, Kanzawa F, Hoshi A. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14: 104-10
79. Nagafuji K, Harada M, Teshima T, et al. Hematopoietic progenitor cells from patients with adult T-cell leukemia-lymphoma are not infected with human T-cell leukemia virus type I. Blood 1993; 82 (9): 2823-8
80. Pawson R, Richardson D, Paglisca A, et al. Adult T cell leukemia\lymphoma in London: clinical experience of 21 cases Leukemia and Lymphoma 1998. In press.
81. Kojima H, Hori M, Shibuya A, et al. Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method. Cancer 1993: 72 (12): 3614-7
82. Kuwazaru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990; 76: 2065-71
83. Lav A, Nightingale S, Taylor GP, et al. Enhanced MDRI gene expression in human T cell leukemia virus 1-infected patients offers new prospects for therapy. Blood 1998; 91: 2467-74
84. Gartenhaus RB, Wang P, Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type 1-transformed lymphocytes alter treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci U S A 1996; 93 (1): 265-8
85. Uittenbogaard MN, Giebler HA, Reisman D, et al. Transcriptional repression of p53 by human T-cell leukemia virus type 1 Tax protein. J Biol Chem 1995; 270 (48): 28503-6
86. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2R/Tac inducer homologous to thioredoxin: Possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 1989; 8: 757-67
87. Yokimozo A, Ono M, Nanri H, et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995; 55: 4293-7
88. Wang J, Kobayashi M, Sakurada K, et al. Possible roles of an adult T-cell leukemia (ATL)-derived tactor/thioredoxin in the drug resistance of ATL to adriamycin. Blood 1997; 89: 2480-7
89. Co-operalive DCF study group (Tobinai K and Shimoyama, M). Phase II study of YK-176 (2′-deoxycoformycin). Proc Jpn Assoc Cancer Res 1990; 49: 376
90. Tobinai K, Shimoyama M, Inoue S, et al. Phase I study of YK-176 (2′-Deoxycoformycin) in patient with adult T-cell leukemia-lymphoma. Jpn J Clin Oncol 1992; 22 (3): 164-71
91. Dearden C, Matules E, Catovsky D. Deoxycoformycin in the treatment of mature T-cell leukemia, Br J Cancer 1991; 64: 903-6
92. Ohno R, Masaoka T, Shirakawa S, et al. Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumordrug and a derivative of bis (2.6-dioxopiperazine). Cancer 1993; 71: 2217-21
93. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 1994; 70: 771-4
94. Smyth J, Prentice H, Proctor S, et al. Deoxycoformycin in the treatment of leukemia and lymphoma. Ann NY Acad Sci 1986; 451: 123-33
95. Tanabe K, Ikegami Y, Ishida R, et al. Inhibition of topoisomerase II by antitumor agents bis (2.6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8
96. Borg A, Yin JAL, Johnson PRE, et al. Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 1996; 94 (4): 713-5
97. Sobue R, Yamauchim T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant 1987; 2 (4): 441-4
98. Ljungman P, Lawler M, Asjo B, et al. Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia [see comments]. Br J Haemalol 1994; 88 (2): 403-5
99. Tamura K, Makino S, Araki Y, et al. Recombinant interferon beta et gamma in the treatment of adult T-cell leukemia. Cancer 1987; 59: 1059-62
100. Ichimaru M, Kamihira S, Moriuchi Y, et al. Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia. Gan To Kagaku Ryoho 1988; 15 (10): 2975-81
101. Ezaki K, Hirano M, Yamada K, et al. A combinational trial of human lymphoblastoid Interferon and bestrabucil (KM 2210) for adult T cell leukemia-lymphoma. Cancer 1991; 68: 695-8
102. Tamura K, Okayama A, Koga K, et al. Total body irradiation as a primary treatment for adult T-cell leukemia. Jpn J Clin Oncol 1983; 13: 313-24
103. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus 1-induced adult T-cell leukemia. Blood 1993; 82 (6): 1701-2
104. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labelled anti-Tac. Blood 1995; 86 (1): 4063-75
105. Takemori N, Hirai K, Onodera R, et al. Satisfactory remission achieved by PUVA therapy in a case of crisis-type adult T-cell leukaemia/lymphoma with generalized cutaneous leukemic cell infiltration. Br J Dermatol 1995; 133: 955-60
106. Gill PS, Harrington Jr W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine [see comments]. N Engl J Med 1995; 132 (26): 1744-8
107. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immun Defic Synd Hum Retrovirol 1996; 13 Suppl. 1: S186-90
108. Teshima T, Akashi K, Shibuya T, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 1989; 65: 127-32
109. Castello G, Mela G, Cerruti A, et al. Azidothymidine and interteron-alpha in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Exp Hematol 1995; 23: 1367-71
110. Tsoi P, Visani G, Ottaviani E, et al. Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. Eur J Haematol 1993; 51: 209-13
111. Isono T, Ogawa K, Seto A, Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk Res 1990: 14 (10): 841-7
112. Oguma S, Imamura Y, Kusumoto Y. Accelerated declining tendency of human T-cell leukemia virus type I carrier rates among younger blood donors in Kumamoto, Japan. Cancer Res 1992; 52: 2620-6
113. Yamaguchi K, Human T-lymphotropic virus type I in Japan. Lancet 1994; 343: 213-6
114. Maeda Y, Myatake J, Sono H, et al. Neu therapeutic effects of retinoid tor adult T cell leukemia. Blood ; 88: 4726-7
115. Ishitsuka K, Suzuki S, Hanado S, et al. Arsenis aas well as retinoic acids have therapeutic potential to adult T cell leukemia. Blood 1997; 90 (S1): 324a
116. Taniguchi Y, Furuke K, Masutani H, et al. Cell cycle inhibition of HTLV-1 transformed T-cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors. Oncology Res 1995; 7: 183-9
117. Goodman D. Vitamin A and retinoids in health and diseases. N Engl J Med 1984; 310: 1023-7
118. Bazarbach A, El-Saddon M, Nasr R, et al. Arsenic trioxyde and interferon-α synergize to induce cell cycle arrest and apoptosis in HTLV-1 transformed, cells. Blood. In press